Second Expert Meeting on Chemical Substance Management for FY2026 to Be Held

News Highlights

The second expert meeting on chemical substance management for fiscal year 2026 will be held. This meeting aims to strengthen the safety management system for chemical substances in medical settings. Specifically, discussions are expected on risk assessment of chemical substances used in pharmaceuticals and medical devices, formulation of management standards, and education/training for healthcare professionals. This suggests the possibility of future regulatory enhancements and guideline revisions, requiring healthcare facility managers to closely monitor developments.

M&A Medical Editorial Department’s Perspective

The expert meeting on chemical substance management underscores the importance of risk management in medical institutions. In particular, strengthened regulations in areas deeply involved in daily operations, such as the storage and management of pharmaceuticals, sterilization and disinfection of medical devices, and waste disposal, could impact operating costs and staffing. For example, if restrictions on the use of certain chemical substances or the introduction of stricter management systems are required, a review of existing capital investments and operational flows will be necessary. This is also a critical point to consider when contemplating M&A, as it pertains to the risks the acquiring party will inherit and the matters the transferring party should address in advance. It should be viewed not merely as a matter of compliance, but as a management issue related to future business continuity.

Key Discussion Points from This News

• The convening of an expert meeting on chemical substance management signals an enhancement of risk management in medical institutions.
• There is a possibility of progress in risk assessment and the formulation of management standards for chemical substances used in pharmaceuticals, medical devices, etc.
• Future regulatory enhancements and guideline revisions may affect the operating costs and staffing of medical institutions.
• In M&A considerations, the chemical substance management system becomes a risk for the acquiring party to inherit and a matter for the transferring party to address.

Practical Questions Arising from This News

• What specific chemical substances will be discussed for strengthened management at this meeting?
• What kind of capital investments or operational changes might medical institutions be required to make due to strengthened management?
• We are considering M&A; what kind of due diligence should be conducted from the perspective of chemical substance management?

If You Feel “Should I Consult?”

The expert meeting on chemical substance management suggests the possibility of future regulatory enhancements. If you have concerns about the types and quantities of chemical substances handled at your facility, your current management system, or are unsure how to assess and manage this risk in the context of M&A, please consider consulting with an expert. Early assessment of the current situation and development of countermeasures will support future business continuity.

M&A Medical (CentralMedience Inc.) supports the business succession of medical corporations, hospitals, and clinics on a completely success-fee basis as an M&A support institution certified by the Small and Medium Enterprise Agency. Consultations are accepted with strict confidentiality. Free consultation here